Parexel to lay off up to 125 transferred GSK employees

By Zachary Brennan contact

- Last updated on GMT

Parexel to lay off up to 125 transferred GSK employees

Related tags: Research triangle park, North carolina, Gsk

Beginning Sept. 30, Massachusetts-based CRO (contract research organization) Parexel will lay off as many as 125 of the 450 employees it brought on from GlaxoSmithKline (GSK) in North Carolina late last year, according to a North Carolina WARN report obtained by Outsourcing-Pharma.com.

A Parexel spokeswoman told us the layoffs are tied to its Research Triangle Park, NC, Sanders Building location, and they come nearly a month after Parexel said it would fire as many as 850 employees in total​.

The WARN report notes that the 125 to be laid off includes 14 clinical monitoring associates, 13 project leaders and 10 project directors. Some of the other positions are listed below:


The 850 layoffs are expected to cost the company between $30m and $40m in employee separation benefits, the company reported in an SEC filing.

Parexel CEO Josef von Rickenbach, who spoke with us​ at DIA in mid-June, said at the time that the GSK employees the service provider brought in would all be coming with work, and he didn’t mention any layoffs.

GSK previously notified the department that it was laying off 180 beginning June 1, according to a different WARN notice. Back in 2010, GSK signed up Parexel​ as one of two CRO strategic partners, alongside PPD.

A local media outlet on Wednesday said in a report​ on the layoffs that a “former Parexel/GSK worker who recently left the firm for another job has remained in contact with former co-workers said colleagues had ‘confirmed’ that ‘a couple hundred people do all have their 5 [minute] meetings in person today with Parexel [human resources] in the Sanders building where we have been working (on GSK's campus) to find out their futures​.’”

Parexel will have a chance to discuss the layoffs further in its quarterly earnings report next Wednesday.

Related news

Show more

Related products

show more

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Q2 Solutions: Corporate Brochure

Q2 Solutions: Corporate Brochure

Q2 Solutions | 17-Apr-2020 | Product Brochure

We are an innovative, progressive and responsive partner with the global experience, medical expertise and focus on quality that is integral to drug, medical...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more